EXAS Stock Overview
Provides cancer screening and diagnostic test products in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Exact Sciences Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$52.70 |
| 52 Week High | US$79.62 |
| 52 Week Low | US$40.62 |
| Beta | 1.27 |
| 11 Month Change | -24.15% |
| 3 Month Change | -10.77% |
| 1 Year Change | -19.39% |
| 33 Year Change | -40.17% |
| 5 Year Change | -35.38% |
| Change since IPO | 257.29% |
Recent News & Updates
Recent updates
Why Investors Shouldn't Be Surprised By Exact Sciences Corporation's (NASDAQ:EXAS) 27% Share Price Plunge
Nov 10
We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt
Sep 25Exact Sciences: Cost Optimization And Product Strength
Aug 18Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Aug 14Exact Sciences: Still No Reason To Own
Jun 11Revenues Working Against Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Following 27% Dive
Jun 02An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 46% Undervalued
Feb 23Investors Don't See Light At End Of Exact Sciences Corporation's (NASDAQ:EXAS) Tunnel
Jan 08Exact Sciences Corporation (NASDAQ:EXAS) Shares Could Be 42% Below Their Intrinsic Value Estimate
Nov 15Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of Debt
Oct 04An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 44% Undervalued
Aug 14Here's Why Exact Sciences (NASDAQ:EXAS) Can Afford Some Debt
Jun 15Calculating The Fair Value Of Exact Sciences Corporation (NASDAQ:EXAS)
Apr 26We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt
Feb 23Shareholder Returns
| EXAS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.9% | -6.5% | -1.0% |
| 1Y | -19.4% | 14.6% | 30.3% |
Return vs Industry: EXAS underperformed the US Biotechs industry which returned 14.6% over the past year.
Return vs Market: EXAS underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| EXAS volatility | |
|---|---|
| EXAS Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: EXAS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: EXAS's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 6,550 | Kevin Conroy | www.exactsciences.com |
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
Exact Sciences Corporation Fundamentals Summary
| EXAS fundamental statistics | |
|---|---|
| Market cap | US$9.98b |
| Earnings (TTM) | -US$214.04m |
| Revenue (TTM) | US$2.69b |
3.6x
P/S Ratio-45.6x
P/E RatioIs EXAS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EXAS income statement (TTM) | |
|---|---|
| Revenue | US$2.69b |
| Cost of Revenue | US$727.88m |
| Gross Profit | US$1.96b |
| Other Expenses | US$2.18b |
| Earnings | -US$214.04m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.16 |
| Gross Margin | 72.96% |
| Net Profit Margin | -7.95% |
| Debt/Equity Ratio | 80.0% |
How did EXAS perform over the long term?
See historical performance and comparison